Lung Cancer
Specialty Channel

Featured Article
Researchers combining selpercatinib with crizotinib were able to target MET-amplified resistance among patients with RET+ NSCLC treated with selpercatinib alone.
Advanced stage NSCLC 80 years and older saw improvement in overall survival when treated with chemotherapy.
Study findings suggest that patients with advanced/metastatic NSCLC have improved survival outcomes after receiving treatment that was guided by biomarker testing, according to research presented at…
In patients with advanced NSCLC that lack targetable mutations, pembrolizumab combined with chemo has shown promising results, according to research presented at the NCCN annual conference.
Which of the following treatments recently received FDA approval for ALK+ Non-Small Cell Lung Cancer?
Patients with advanced/metastatic NSCLC have improved survival after treatment guided by biomarker testing, according to research presented at the NCCN Annual Conference.
Bevacizumab combined with S-1 chemotherapy was shown to be active in patients with pretreated, advanced, non-squamous NSCLC.
Patients with EGFR-positive NSCLC had significantly longer disease-free survival (DFS) when given osimertinib therapy.
The FDA has approved lorlatinib for the treatment of patients with metastatic NSCLC with ALK-positive tumors, as detected by an FDA-approved test.

News

Researchers combining selpercatinib with crizotinib were able to target MET-amplified resistance among patients with RET+ NSCLC treated with selpercatinib alone.
Advanced stage NSCLC 80 years and older saw improvement in overall survival when treated with chemotherapy.
Study findings suggest that patients with advanced/metastatic NSCLC have improved survival outcomes after receiving treatment that was guided by biomarker testing, according to research presented at…
In patients with advanced NSCLC that lack targetable mutations, pembrolizumab combined with chemo has shown promising results, according to research presented at the NCCN annual conference.

Interactive Features

Which of the following treatments recently received FDA approval for ALK+ Non-Small Cell Lung Cancer?
True or false: Moderate neutropenia levels predict improved OS in NSCLC after gem-carbo therapy.
True or False: Population-based death rates from NSCLC in the United States dramatically declined between 2013 and 2016.
True or false: A liquid biopsy companion diagnostic was recently FDA-approved to help identify ROS-mutated NSCLC.
Stay in the know.
OncNet Newsletter